A new MDCK suspension line cultivated in a fully defined medium in stirred-tank 
and wave bioreactor

Lohr, V.; Genzel, Y.; Behrendt, I.; Scharfenberg, K.; Reichl, U.

doi:10.1016/j.vaccine.2010.07.004

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor

MPS-Authors

/persons/resource/persons86389

Lohr, V.
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society;

/persons/resource/persons86303

Genzel, Y.
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society;

/persons/resource/persons86251

Behrendt, I.
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society;

/persons/resource/persons86448

Reichl, U.
Otto-von-Guericke-Universität Magdeburg;
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Lohr, V., Genzel, Y., Behrendt, I., Scharfenberg, K., & Reichl, U. (2010). A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine, 28(38), 6256-6264. doi:10.1016/j.vaccine.2010.07.004.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0013-90B1-3

Abstract

An adherently growing MDCK cell line was adapted in a two-step process in a fully defined medium and in suspension. The resulting MDCK.SUS2 cells were subsequently evaluated for their potential as host cells for influenza vaccine production in two lab-scale bioreactors (wave and stirred-tank). Cell concentrations up to 2.3×106 cells/mL were obtained after 96 h, which is slightly higher than cell concentrations obtained with adherent MDCK cells cultivated on microcarriers (2 g/L). Infections with influenza A/PR/8/34 and B/Malaysia resulted in high virus titers (2.90 and 2.75 logHAunits/100uL, respectively). The monitoring of extracellular metabolites, including amino acids, revealed a change in some of the metabolite consumption or release profiles, which indicates changes in metabolism during the adaptation process. Overall, the MDCK.SUS2 cell line represents a new cell substrate for a robust influenza vaccine production in a fully defined process. © 2010 Elsevier Ltd. All rights reserved. [accessed September 21st, 2010]